Literature DB >> 25136255

Irritable bowel syndrome: current and emerging treatment options.

Lauren Peyton, Joy Greene.   

Abstract

Irritable bowel syndrome, a functional gastrointestinal disorder of uncertain pathophysiology, affects up to 55 million Americans. Medications available or in development include antispasmodics, antidepressants, and antidiarrheals.

Entities:  

Year:  2014        PMID： 25136255      PMCID： PMC4123807     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  26 in total

Review 1.  Probiotics, gut microbiota and health.

Authors:  M-J Butel
Journal:  Med Mal Infect       Date:  2013-11-28       Impact factor: 2.152

Review 2.  An evidence-based position statement on the management of irritable bowel syndrome.

Authors:  Lawrence J Brandt; William D Chey; Amy E Foxx-Orenstein; Lawrence R Schiller; Philip S Schoenfeld; Brennan M Spiegel; Nicholas J Talley; Eamonn M M Quigley
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

3.  Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.

Authors:  R W Chapman; V Stanghellini; M Geraint; M Halphen
Journal:  Am J Gastroenterol       Date:  2013-07-09       Impact factor: 10.864

Review 4.  Current and novel therapeutic options for irritable bowel syndrome management.

Authors:  M Camilleri; V Andresen
Journal:  Dig Liver Dis       Date:  2009-08-08       Impact factor: 4.088

Review 5.  Role of radiologic imaging in irritable bowel syndrome: evidence-based review.

Authors:  Owen J O'Connor; Sean E McSweeney; Sebastian McWilliams; Siobhan O'Neill; Fergus Shanahan; Eamonn M M Quigley; Michael M Maher
Journal:  Radiology       Date:  2011-12-09       Impact factor: 11.105

6.  Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.

Authors:  W D Chey; D A Drossman; J F Johanson; C Scott; R M Panas; R Ueno
Journal:  Aliment Pharmacol Ther       Date:  2012-01-18       Impact factor: 8.171

7.  Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Authors:  Leonard S Dove; Anthony Lembo; Charles W Randall; Ronald Fogel; David Andrae; J Michael Davenport; Gail McIntyre; June S Almenoff; Paul S Covington
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

8.  Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

Authors:  F Cremonini; J P Nicandro; V Atkinson; R Shringarpure; E Chuang; A Lembo
Journal:  Aliment Pharmacol Ther       Date:  2012-07-10       Impact factor: 8.171

Review 9.  A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome.

Authors:  Nourieh Hoveyda; Carl Heneghan; Kamal R Mahtani; Rafael Perera; Nia Roberts; Paul Glasziou
Journal:  BMC Gastroenterol       Date:  2009-02-16       Impact factor: 3.067

10.  Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome(D-IBS).

Authors:  Jianhua Sun; Xiaoliang Wu; Yunfang Meng; Jie Cheng; Houxu Ning; Yongjun Peng; Lixia Pei; Wei Zhang
Journal:  BMC Complement Altern Med       Date:  2015-09-29       Impact factor: 3.659
View more
  3 in total

Review 1.  Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature.

Authors:  Nathaniel Aviv Cohen; Nitsan Maharshak
Journal:  Dig Dis Sci       Date:  2017-03-17       Impact factor: 3.199

Review 2.  Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance.

Authors:  Albert Orock; Tian Yuan; Beverley Greenwood-Van Meerveld
Journal:  Front Pain Res (Lausanne)       Date:  2021-01-21

3.  Acupuncture for irritable bowel syndrome: study protocol for a multicenter randomized controlled trial.

Authors:  Li-Xia Pei; Hao Geng; Hao Chen; Xiao-Liang Wu; Lu Chen; Jun-Ling Zhou; Lu Ju; Gao Lu; Wan-Li Xu; Shan Qin; Jing Guo; Eun Mee Yang; Jian-Hua Sun
Journal:  Trials       Date:  2018-10-01       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.